ezetimibe has been researched along with orlistat in 9 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (orlistat) | Trials (orlistat) | Recent Studies (post-2010) (orlistat) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 1,432 | 274 | 539 |
| Protein | Taxonomy | ezetimibe (IC50) | orlistat (IC50) |
|---|---|---|---|
| Phosphatidylserine lipase ABHD16A | Homo sapiens (human) | 0.1 | |
| Pancreatic triacylglycerol lipase | Sus scrofa (pig) | 0.4214 | |
| Lipoprotein lipase | Homo sapiens (human) | 0.066 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.42 | |
| Hepatic triacylglycerol lipase | Homo sapiens (human) | 0.003 | |
| Pancreatic triacylglycerol lipase | Homo sapiens (human) | 0.3253 | |
| Translocator protein | Rattus norvegicus (Norway rat) | 1 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.42 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.1903 | |
| Fatty acid synthase | Homo sapiens (human) | 2.99 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.01 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.05 | |
| Diacylglycerol lipase-alpha | Mus musculus (house mouse) | 0.02 | |
| Lysophosphatidylserine lipase ABHD12 | Homo sapiens (human) | 0.1682 | |
| Diacylglycerol lipase-beta | Homo sapiens (human) | 0.24 | |
| Monoacylglycerol lipase ABHD6 | Homo sapiens (human) | 0.03 | |
| Acyl-protein thioesterase 2 | Rattus norvegicus (Norway rat) | 0.17 | |
| Diacylglycerol lipase-alpha | Homo sapiens (human) | 0.2677 | |
| Endothelial lipase | Homo sapiens (human) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Song, Z; Wang, X; Xing, D; Xue, J; Zhang, R | 1 |
| Elisaf, MS; Filippatos, TD; Georgoula, M; Kiortsis, DN; Mikhailidis, DP; Nakou, ES; Tselepis, AD | 1 |
| Derdemezis, CS; Elisaf, MS; Filippatos, TD; Kiortsis, DN; Mikhailidis, DP; Nakou, ES; Tselepis, AD | 1 |
| Filippatos, TD; Mikhailidis, DP | 1 |
| Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES | 1 |
| Agouridis, AP; Bairaktari, ET; Elisaf, MS; Filippatos, TD; Kostara, C; Nakou, ES | 1 |
2 review(s) available for ezetimibe and orlistat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Lipid-lowering drugs acting at the level of the gastrointestinal tract.
Topics: Animals; Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Clinical Trials as Topic; Ezetimibe; Gastrointestinal Tract; Humans; Lactones; Orlistat; Phytosterols | 2009 |
4 trial(s) available for ezetimibe and orlistat
| Article | Year |
|---|---|
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Mass Index; Caloric Restriction; Cholesterol, LDL; Diet, Fat-Restricted; Drug Therapy, Combination; Ezetimibe; Female; gamma-Glutamyltransferase; Homeostasis; Humans; Hypercholesterolemia; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Treatment Outcome; Uric Acid | 2008 |
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.
Topics: Adult; Anti-Obesity Agents; Anticholesteremic Agents; Aryldialkylphosphatase; Azetidines; Body Mass Index; Cholesterol, HDL; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipidemias; Lactones; Linear Models; Lipoproteins, HDL2; Lipoproteins, HDL3; Male; Middle Aged; Obesity; Orlistat; Phospholipases A2; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant | 2009 |
The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Apolipoprotein C-II; Apolipoprotein C-III; Azetidines; Diet, Fat-Restricted; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Triglycerides | 2010 |
3 other study(ies) available for ezetimibe and orlistat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1.
Topics: Anticholesteremic Agents; Binding Sites; Cell Line, Tumor; Drug Design; Ezetimibe; Gene Expression Regulation; Humans; Hypercholesterolemia; Lipase; Membrane Transport Proteins; Molecular Docking Simulation; Molecular Dynamics Simulation; Orlistat; Pancreas | 2021 |